Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 12/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | PDCD1LG2 | Q9BQ51 | 9/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25313699 | 1.00 | CD274 (0.38) | CD274PDCD1SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL25311371 | 0.88 | CD274 (0.36) | CD274PDCD1PDCD1LG2CRBN | |
| SCHEMBL25313884 | 0.88 | CD274 (0.36) | CD274PDCD1PDCD1LG2CRBN | |
| SCHEMBL25313374 | 0.86 | KCNA5 (0.40) | CD274PDCD1SLC6A3SLC6A4PDCD1LG2 | |
| SCHEMBL25313410 | 0.86 | KCNA5 (0.40) | CD274PDCD1SLC6A3SLC6A4PDCD1LG2 | |
| SCHEMBL25311117 | 0.79 | CD274 (0.38) | CD274PDCD1PDCD1LG2CRBNDDB1 | |
| SCHEMBL30482532 | 0.79 | CD274 (0.38) | CD274PDCD1PDCD1LG2CRBNDDB1 | |
| SCHEMBL30482549 | 0.79 | CD274 (0.38) | CD274PDCD1PDCD1LG2CRBNDDB1 | |
| SCHEMBL25315591 | 0.79 | CD274 (0.38) | CD274PDCD1PDCD1LG2CRBNDDB1 | |
| SCHEMBL25309676 | 0.76 | CD274 (0.37) | CD274PDCD1PDCD1LG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240034717-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA A/S (DK) | 2024-02-01 | — | — | US | disclosed |
| EP-4217065-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | Saniona A/S (DK) | 2023-08-02 | — | — | EP | disclosed |
| CN-116368112-A | Novel potassium channel inhibitors | 萨尼奥纳有限责任公司 | 2023-06-30 | — | — | CN | disclosed |
| WO-2022063767-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA A/S (DK) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240034717-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNN2, KCNJ2, KCNN1 | CD274 4497/4885PDCD1 3549/4885SLC6A3 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.